항체 치료제 시장 : 제품별, 형태별, 표적별, 유래별, 투여 경로별, 치료 분야별, 최종사용자별, 지역별 - 세계 예측(-2035년)

The antibody therapeutics market is projected to reach USD 597.1 billion by 2035, up from USD 311.2 billion in 2026, at a CAGR of 7.5% over the forecast period.

Market growth is driven by increasing demand for highly targeted biologic therapies across oncology, autoimmune diseases, inflammatory disorders, and other chronic conditions. Monoclonal antibodies remain a major contributor to growth. Advances in antibody engineering are also expanding the market beyond conventional monoclonal antibodies to include bispecific and multispecific antibodies, antibody fragments, and antibody-drug conjugates (ADCs).

By product, the commercialized antibody therapeutics market segment accounted for the largest share of the market in 2025.

The market is segmented into commercialized products (Keytruda, Dupixent, Skyrizi, Darzalex, Vyvgart, and other commercialized products) and pipeline products (Ivonescimab, Sacituzumab tirumotecan (Sac-TMT), Izalontamab brengitecan, and other pipeline products). In 2025, the commercialized antibody therapeutics segment accounted for the largest share of the market, driven by strong clinical adoption and revenue contributions from approved monoclonal antibodies, immune checkpoint inhibitors, anti-inflammatory biologics, ADCs, and bispecific antibodies. This dominance reflects the proven efficacy, target specificity, established safety profiles, and broad use of these therapies across oncology, autoimmune, inflammatory, hematologic, ophthalmic, and rare disease indications.

In 2025, North America accounted for the largest share of the overall antibody therapeutics market.

The US is the largest contributor to North America's antibody therapeutics market, supported by a dense ecosystem of leading biopharmaceutical companies, academic medical centers, research institutes, clinical-trial networks, and specialized biologics manufacturers. The region benefits from high healthcare spending, strong funding for biologics R&D, early adoption of targeted therapies, and established regulatory pathways that support the development and commercialization of monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation antibody formats.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
• By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%

AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron Pharmaceuticals Inc. (US), Boehringer Ingelheim International GmbH (Germany), MacroGenics, Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Daiichi Sankyo, Inc. (Japan), AstraZeneca (UK), Celltrion (South Korea), UCB, Inc. (Belgium), Innovent Biologics (China), Emergent BioSolutions Inc. (US), Immunocore Ltd. (UK).

Research Coverage:

This research report categorizes antibody therapeutics market by product (commercialized products, pipeline products), format (monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, antibody drug conjugates), target (PD-1/PD-L1, TNF alpha, cytokine/inflammatory pathway targets, HER2, other targets), source (human, humanized, chimeric, other sources), route of administration (intravenous, subcutaneous, other routes of administration), therapeutic area (autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, other therapeutic areas), end user (hospitals & specialty care centers, long-term care facilities, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the antibody therapeutics market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, products, key strategies, new product launches, acquisitions, and recent developments associated with the antibody therapeutics market. This report also covers the competitive analysis of upcoming startups in the antibody therapeutics market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue for the antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights into the following:

• Analysis of key drivers (strong approval and pipeline momentum), restraints (long, capital-intensive development), opportunities (expansion beyond oncology), and challenges (safety and post-approval obligations) influencing the growth of the antibody therapeutics market
• Product Approvals: Detailed insights on newly approved products of the antibody therapeutics market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the antibody therapeutics market across varied regions
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the antibody therapeutics market
• Pipeline Analysis: Comprehensive information about antibody therapeutics under clinical trials
• Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including AbbVie Inc. (US), Merck (US), Johnson & Johnson (US), Regeneron Pharmaceuticals Inc. (US), Sanofi (France), Amgen Inc. (US), GlaxoSmithKline plc (UK), among several others, are key players in the antibody therapeutics market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW
• 3.2 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION & REGION
• 3.3 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT
• 3.4 ANTIBODY THERAPEUTICS MARKET SHARE, BY SOURCE, 2026 VS. 2035 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising clinical success and regulatory approvals of antibody therapeutics
    • 4.2.1.2 Technological advancements in antibody engineering and bispecific platforms
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Patent expirations and biosimilar competition intensifying pricing pressure
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion of antibody therapeutics into non-oncology therapeutic areas
    • 4.2.3.2 Rapid expansion of bispecific and multispecific antibody platforms
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL ANTIBODY THERAPEUTICS MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 LIST OF KEY ANTIBODY CDMOS/CMOS & SERVICE PROVIDERS
  • 5.4.2 MANUFACTURING SITES & CAPACITY EXPANSION OF KEY ANTIBODY MANUFACTURERS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY KEY PLAYER (2025)
  • 5.5.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT (2023-2025)
  • 5.5.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION (2025)
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 IMPACT OF 2025 US TARIFFS ON GLOBAL ANTIBODY THERAPEUTICS MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 PRICE IMPACT ANALYSIS
  • 5.9.3 IMPACT ON COUNTRY/REGION
    • 5.9.3.1 North America
    • 5.9.3.2 Europe
    • 5.9.3.3 Asia Pacific
  • 5.9.4 IMPACT ON END-USE INDUSTRIES
    • 5.9.4.1 Hospitals
    • 5.9.4.2 Specialty clinics & cancer centers
    • 5.9.4.3 Other specialty care settings

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 INTRODUCTION
• 6.2 KEY EMERGING TECHNOLOGIES
  • 6.2.1 BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING
  • 6.2.2 NEXT-GENERATION ANTIBODY-DRUG CONJUGATES (ADCS)
  • 6.2.3 FC ENGINEERING & HALF-LIFE EXTENSION
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 ANTIBODY DISCOVERY & ENGINEERING PLATFORMS
  • 6.3.2 GLYCOENGINEERING & EXPRESSION-SYSTEM ENGINEERING
• 6.4 COMPLEMENTARY TECHNOLOGIES
  • 6.4.1 SUBCUTANEOUS DELIVERY & CO-FORMULATION
  • 6.4.2 COMPANION DIAGNOSTICS & BIOMARKER-GUIDED PATIENT SELECTION
• 6.5 TECHNOLOGY/PRODUCT ROADMAP
• 6.6 FUTURE APPLICATIONS
• 6.7 PIPELINE ANALYSIS
  • 6.7.1 KEY PIPELINE PRODUCTS & INDICATION EXPANSION
  • 6.7.2 DISCONTINUED/DEPRIORITIZED PIPELINE ASSETS
• 6.8 IMPACT OF AI/GEN AI ON GLOBAL ANTIBODY THERAPEUTICS MARKET
  • 6.8.1 TOP USE CASES & MARKET POTENTIAL
  • 6.8.2 CASE STUDIES OF AI IMPLEMENTATION IN GLOBAL ANTIBODY THERAPEUTICS MARKET
  • 6.8.3 INTERCONNECTED ADJACENT ECOSYSTEM & IMPACT ON MARKET PLAYERS
  • 6.8.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN GLOBAL ANTIBODY THERAPEUTICS MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM END USERS
• 8.5 MARKET PROFITABILITY

9 ANTIBODY THERAPEUTICS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 COMMERCIALIZED PRODUCTS
  • 9.2.1 KEYTRUDA
    • 9.2.1.1 Earlier-stage use, combination regimens, and subcutaneous conversion to sustain Keytruda leadership
  • 9.2.2 DUPIXENT
    • 9.2.2.1 Expansion across type 2 inflammatory diseases and age groups to support continued Dupixent growth
  • 9.2.3 SKYRIZI
    • 9.2.3.1 Durable IL-23 efficacy and gastroenterology expansion to reinforce Skyrizi adoption
  • 9.2.4 DARZALEX
    • 9.2.4.1 Frontline combinations and rapid subcutaneous dosing to extend Darzalex franchise
  • 9.2.5 VYVGART
    • 9.2.5.1 FcRn class expansion and self-administered delivery to accelerate Vyvgart uptake
  • 9.2.6 OTHER COMMERCIALIZED PRODUCTS
• 9.3 PIPELINE PRODUCTS
  • 9.3.1 IVONESCIMAB
    • 9.3.1.1 Dual PD-1/VEGF blockade and broad Phase III development to support Ivonescimab's global potential
  • 9.3.2 SACITUZUMAB TIRUMOTECAN (SAC-TMT)
    • 9.3.2.1 TROP2 validation and topoisomerase-I payload activity to drive sac-TMT across solid tumors
  • 9.3.3 IZALONTAMAB BRENGITECAN
    • 9.3.3.1 Dual EGFR/HER3 targeting and ADC delivery to support iza-bren in resistant epithelial cancers
  • 9.3.4 OTHER PIPELINE PRODUCTS

10 ANTIBODY THERAPEUTICS MARKET, BY FORMAT

• 10.1 INTRODUCTION
• 10.2 MONOCLONAL ANTIBODIES
  • 10.2.1 BROAD CLINICAL VALIDATION AND REPEATED INDICATION EXPANSION TO MAKE MONOCLONAL ANTIBODIES LARGEST FORMAT
• 10.3 POLYCLONAL ANTIBODIES
  • 10.3.1 EMERGENCY PREPAREDNESS AND SPECIALIST USE TO SUSTAIN DEMAND FOR POLYCLONAL ANTIBODIES
• 10.4 ANTIBODY FRAGMENTS
  • 10.4.1 IMPROVED TISSUE PENETRATION AND LOCAL DELIVERY TO SUPPORT GROWTH OF ANTIBODY FRAGMENTS
• 10.5 BISPECIFIC ANTIBODIES
  • 10.5.1 RAPID APPROVALS AND DUAL-TARGET MECHANISMS TO MAKE BISPECIFIC ANTIBODIES HIGH-GROWTH FORMAT
• 10.6 ANTIBODY-DRUG CONJUGATES (ADCS)
  • 10.6.1 DM1
    • 10.6.1.1 Established HER2 use and regional follow-on products to sustain the DM1 payload segment
  • 10.6.2 MMAE
    • 10.6.2.1 Broad target applicability and large approved product base to support MMAE growth
  • 10.6.3 SN-38
    • 10.6.3.1 TROP-2 validation and bystander activity to support continued SN-38 demand
  • 10.6.4 DM4
    • 10.6.4.1 Folate receptor-alpha-based patient selection to anchor DM4 payload segment
  • 10.6.5 OTHER PAYLOAD TYPES
• 10.7 OTHER ANTIBODY THERAPEUTICS

11 ANTIBODY THERAPEUTICS MARKET, BY TARGET

• 11.1 INTRODUCTION
• 11.2 PD-1/PD-L1
  • 11.2.1 BROAD ONCOLOGY USE AND COMBINATION STRATEGIES TO SUSTAIN PD-1/PD-L1 DEMAND
• 11.3 TNF ALPHA
  • 11.3.1 BIOSIMILAR ACCESS AND ENTRENCHED GUIDELINE USE TO SUSTAIN TNF ALPHA VOLUMES
• 11.4 CYTOKINE/INFLAMMATORY PATHWAY TARGETS
  • 11.4.1 INTERLEUKIN AND INFLAMMATORY-PATHWAY EXPANSION TO DRIVE CHRONIC DISEASE ADOPTION
• 11.5 HER2
  • 11.5.1 ADC INNOVATION AND BIOMARKER-LED EXPANSION TO STRENGTHEN HER2-TARGETED ANTIBODIES
• 11.6 OTHER TARGETS

12 ANTIBODY THERAPEUTICS MARKET, BY SOURCE

• 12.1 INTRODUCTION
• 12.2 HUMAN
  • 12.2.1 LOWER IMMUNOGENICITY AND CHRONIC-USE EXPANSION TO SUPPORT FULLY HUMAN ANTIBODIES
• 12.3 HUMANIZED
  • 12.3.1 LARGE BLOCKBUSTER BASE AND ENGINEERING FLEXIBILITY TO KEEP HUMANIZED ANTIBODIES DOMINANT
• 12.4 CHIMERIC
  • 12.4.1 ESTABLISHED CLINICAL USE AND BIOSIMILAR ACCESS TO SUSTAIN CHIMERIC-ANTIBODY VOLUMES
• 12.5 OTHER SOURCES

13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

• 13.1 INTRODUCTION
• 13.2 INTRAVENOUS
  • 13.2.1 COMPLEX ONCOLOGY AND HOSPITAL-BASED DOSING TO MAKE INTRAVENOUS ADMINISTRATION LARGEST ROUTE
• 13.3 SUBCUTANEOUS
  • 13.3.1 LOWER ADMINISTRATION BURDEN AND HOME-CARE POTENTIAL TO MAKE SUBCUTANEOUS DELIVERY FASTEST-GROWING ROUTE
• 13.4 OTHER ROUTES OF ADMINISTRATION

14 ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA

• 14.1 INTRODUCTION
• 14.2 AUTOIMMUNE & INFLAMMATORY DISEASES
  • 14.2.1 CHRONIC DISEASE BURDEN AND TARGETED BIOLOGIC SEQUENCING TO SUSTAIN DEMAND
• 14.3 ONCOLOGY
  • 14.3.1 EARLIER-LINE IMMUNOTHERAPY, ADCS, AND BISPECIFICS TO BOOST MARKET GROWTH
• 14.4 HEMATOLOGY
  • 14.4.1 DEEPENING RESPONSE EXPECTATIONS AND OUTPATIENT FORMATS TO ACCELERATE HEMATOLOGY ANTIBODY USE
• 14.5 INFECTIOUS DISEASES
  • 14.5.1 LONG-ACTING PROPHYLAXIS AND PREPAREDNESS PROGRAMS TO SUPPORT MARKET GROWTH
• 14.6 BONE DISORDER
  • 14.6.1 POPULATION AGING, FRACTURE PREVENTION, AND BIOSIMILAR ACCESS TO SUSTAIN DEMAND
• 14.7 IMMUNOLOGY
  • 14.7.1 TYPE 2 DISEASE EXPANSION AND BIOMARKER-LED TREATMENT TO DRIVE GROWTH
• 14.8 NEUROLOGY
  • 14.8.1 DISEASE-MODIFYING ANTIBODIES AND EASIER ADMINISTRATION TO MAKE NEUROLOGY HIGH-GROWTH AREA
• 14.9 OTHER THERAPEUTIC AREAS

15 ANTIBODY THERAPEUTICS MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 HOSPITALS & SPECIALTY CARE CENTERS
  • 15.2.1 COMPLEX INFUSION PROTOCOLS AND MULTIDISCIPLINARY CARE TO KEEP HOSPITALS AND SPECIALTY CENTERS DOMINANT
• 15.3 LONG-TERM CARE FACILITIES
  • 15.3.1 AGING POPULATIONS AND SCHEDULED CHRONIC BIOLOGIC CARE TO SUPPORT GRADUAL LONG-TERM CARE ADOPTION
• 15.4 OTHER END USERS

16 ANTIBODY THERAPEUTICS MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 US
    • 16.2.1.1 Regulatory speed and high-value specialty care to drive market growth
  • 16.2.2 CANADA
    • 16.2.2.1 Public reimbursement and coordinated cancer care to support steady antibody adoption
• 16.3 EUROPE
  • 16.3.1 GERMANY
    • 16.3.1.1 AMNOG assessment and dense specialty networks to support high-value antibody use
  • 16.3.2 UK
    • 16.3.2.1 MHRA agility and NHS specialist pathways to sustain targeted antibody uptake
  • 16.3.3 FRANCE
    • 16.3.3.1 National HTA, oncology infrastructure, and biologics investment to support market growth
  • 16.3.4 ITALY
    • 16.3.4.1 AIFA monitoring and hospital oncology networks to enable controlled antibody expansion
  • 16.3.5 SPAIN
    • 16.3.5.1 Hospital pharmacy expertise and national positioning reports to support measured adoption
  • 16.3.6 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 CHINA
    • 16.4.1.1 Domestic bispecific and ADC innovation to accelerate antibody market expansion
  • 16.4.2 JAPAN
    • 16.4.2.1 Universal coverage and first-in-class launches to support stable high-value adoption
  • 16.4.3 SOUTH KOREA
    • 16.4.3.1 Biologics manufacturing scale and biosimilar leadership to support rapid market development
  • 16.4.4 INDIA
    • 16.4.4.1 Cost-efficient biosimilars and expanding specialty care to broaden antibody access
  • 16.4.5 AUSTRALIA
    • 16.4.5.1 Specialist centers and efficient regulation to support adoption of differentiated antibodies
  • 16.4.6 REST OF ASIA PACIFIC
• 16.5 LATIN AMERICA
  • 16.5.1 BRAZIL
    • 16.5.1.1 Large public and private care systems to anchor Latin American antibody demand
  • 16.5.2 MEXICO
    • 16.5.2.1 Large institutional purchasers and private oncology networks to support rising adoption
  • 16.5.3 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST
  • 16.6.1 GCC COUNTRIES
    • 16.6.1.1 Saudi Arabia
      • 16.6.1.1.1 Vision 2030 investment and SFDA modernization to accelerate specialty-biologic access
    • 16.6.1.2 UAE
      • 16.6.1.2.1 Private insurance, medical hubs, and regulatory reforms to support premium antibody uptake
    • 16.6.1.3 Rest of GCC Countries
  • 16.6.2 REST OF MIDDLE EAST
• 16.7 AFRICA
  • 16.7.1 BIOSIMILARS AND REGIONAL MANUFACTURING INITIATIVES OFFER A PATHWAY TO WIDER ACCESS

17 COMPETITIVE LANDSCAPE

• 17.1 INTRODUCTION
• 17.2 KEY STRATEGIES/RIGHT TO WIN
  • 17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIBODY THERAPEUTICS MARKET
• 17.3 REVENUE ANALYSIS, 2023-2025
• 17.4 MARKET SHARE ANALYSIS, 2025
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 STARS
  • 17.5.2 EMERGING LEADERS
  • 17.5.3 PERVASIVE PLAYERS
  • 17.5.4 PARTICIPANTS
  • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 17.5.5.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Format footprint
    • 17.5.5.4 Source footprint
    • 17.5.5.5 Route of administration footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 PROGRESSIVE COMPANIES
  • 17.6.2 RESPONSIVE COMPANIES
  • 17.6.3 DYNAMIC COMPANIES
  • 17.6.4 STARTING BLOCKS
  • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 17.6.5.1 Detailed list of key startups/SMEs
    • 17.6.5.2 Competitive benchmarking of key startups/SMEs
• 17.7 COMPANY VALUATION & FINANCIAL METRICS
  • 17.7.1 COMPANY VALUATION
  • 17.7.2 FINANCIAL METRICS
• 17.8 BRAND/PRODUCT COMPARISON
• 17.9 COMPETITIVE SCENARIOS
  • 17.9.1 PRODUCT APPROVALS
  • 17.9.2 DEALS
  • 17.9.3 OTHER DEVELOPMENTS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 18.1.1.1 Business overview
    • 18.1.1.2 Products offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Product approvals
      • 18.1.1.3.2 Deals
      • 18.1.1.3.3 Expansions
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Key strengths
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses & competitive threats
  • 18.1.2 ABBVIE INC.
    • 18.1.2.1 Business overview
    • 18.1.2.2 Products offered
    • 18.1.2.3 Recent developments
      • 18.1.2.3.1 Product approvals
      • 18.1.2.3.2 Deals
      • 18.1.2.3.3 Expansions
    • 18.1.2.4 MnM view
      • 18.1.2.4.1 Key strengths
      • 18.1.2.4.2 Strategic choices
      • 18.1.2.4.3 Weaknesses & competitive threats
  • 18.1.3 AMGEN INC.
    • 18.1.3.1 Business overview
    • 18.1.3.2 Products offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Product approvals
      • 18.1.3.3.2 Deals
      • 18.1.3.3.3 Expansions
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Key strengths
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses & competitive threats
  • 18.1.4 REGENERON PHARMACEUTICALS, INC.
    • 18.1.4.1 Business overview
    • 18.1.4.2 Products offered
    • 18.1.4.3 Recent developments
      • 18.1.4.3.1 Product approvals
      • 18.1.4.3.2 Deals
      • 18.1.4.3.3 Expansions
    • 18.1.4.4 MnM view
      • 18.1.4.4.1 Key strengths
      • 18.1.4.4.2 Strategic choices
      • 18.1.4.4.3 Weaknesses & competitive threats
  • 18.1.5 ASTRAZENECA PLC
    • 18.1.5.1 Business overview
    • 18.1.5.2 Products offered
    • 18.1.5.3 Recent developments
      • 18.1.5.3.1 Product approvals
      • 18.1.5.3.2 Deals
      • 18.1.5.3.3 Expansions
    • 18.1.5.4 MnM view
      • 18.1.5.4.1 Key strengths
      • 18.1.5.4.2 Strategic choices
      • 18.1.5.4.3 Weaknesses & competitive threats
  • 18.1.6 BIOGEN INC.
    • 18.1.6.1 Business overview
    • 18.1.6.2 Products offered
    • 18.1.6.3 Recent developments
      • 18.1.6.3.1 Product approvals
      • 18.1.6.3.2 Deals
      • 18.1.6.3.3 Expansions
    • 18.1.6.4 MnM view
      • 18.1.6.4.1 Key strengths
      • 18.1.6.4.2 Strategic choices
      • 18.1.6.4.3 Weaknesses & competitive threats
  • 18.1.7 MERCK & CO., INC.
    • 18.1.7.1 Business overview
    • 18.1.7.2 Products offered
    • 18.1.7.3 Recent developments
      • 18.1.7.3.1 Product approvals
      • 18.1.7.3.2 Deals
    • 18.1.7.4 MnM view
      • 18.1.7.4.1 Key strengths
      • 18.1.7.4.2 Strategic choices
      • 18.1.7.4.3 Weaknesses & competitive threats
  • 18.1.8 NOVARTIS AG
    • 18.1.8.1 Business overview
    • 18.1.8.2 Products offered
    • 18.1.8.3 Recent developments
      • 18.1.8.3.1 Product approvals
      • 18.1.8.3.2 Deals
    • 18.1.8.4 MnM view
      • 18.1.8.4.1 Key strengths
      • 18.1.8.4.2 Strategic choices
      • 18.1.8.4.3 Weaknesses & competitive threats
  • 18.1.9 DAIICHI SANKYO COMPANY, LIMITED
    • 18.1.9.1 Business overview
    • 18.1.9.2 Products offered
    • 18.1.9.3 Recent developments
      • 18.1.9.3.1 Product approvals
      • 18.1.9.3.2 Deals
  • 18.1.10 GSK PLC
    • 18.1.10.1 Business overview
    • 18.1.10.2 Products offered
    • 18.1.10.3 Recent developments
      • 18.1.10.3.1 Product approvals
  • 18.1.11 SANOFI
    • 18.1.11.1 Business overview
    • 18.1.11.2 Products offered
    • 18.1.11.3 Recent developments
      • 18.1.11.3.1 Product approvals
      • 18.1.11.3.2 Deals
  • 18.1.12 GILEAD SCIENCES, INC.
    • 18.1.12.1 Business overview
    • 18.1.12.2 Products offered
    • 18.1.12.3 Recent developments
      • 18.1.12.3.1 Product approvals
  • 18.1.13 JAZZ PHARMACEUTICALS PLC
    • 18.1.13.1 Business overview
    • 18.1.13.2 Products offered
    • 18.1.13.3 Recent developments
      • 18.1.13.3.1 Product approvals
      • 18.1.13.3.2 Deals
  • 18.1.14 PFIZER INC.
    • 18.1.14.1 Business overview
    • 18.1.14.2 Products offered
    • 18.1.14.3 Recent developments
      • 18.1.14.3.1 Product approvals
      • 18.1.14.3.2 Deals
  • 18.1.15 JOHNSON & JOHNSON
    • 18.1.15.1 Business overview
    • 18.1.15.2 Products offered
    • 18.1.15.3 Recent developments
      • 18.1.15.3.1 Product approvals
      • 18.1.15.3.2 Deals
  • 18.1.16 ELI LILLY AND COMPANY
    • 18.1.16.1 Business overview
    • 18.1.16.2 Products offered
    • 18.1.16.3 Recent developments
      • 18.1.16.3.1 Product approvals
      • 18.1.16.3.2 Expansions
  • 18.1.17 H. LUNDBECK A/S
    • 18.1.17.1 Business overview
    • 18.1.17.2 Products offered
    • 18.1.17.3 Recent developments
      • 18.1.17.3.1 Product approvals
• 18.2 OTHER PLAYERS
  • 18.2.1 CHUGAI PHARMACEUTICAL CO., LTD.
  • 18.2.2 AKESO, INC.
  • 18.2.3 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
  • 18.2.4 CELLTRION, INC.
  • 18.2.5 CSL BEHRING
  • 18.2.6 OTSUKA AMERICA PHARMACEUTICAL, INC.
  • 18.2.7 LEPU BIOPHARMA CO., LTD.
  • 18.2.8 SINOCELLTECH GROUP LTD.
  • 18.2.9 SYNERMORE BIOLOGICS
  • 18.2.10 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
  • 18.2.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH DATA
  • 19.1.1 SECONDARY DATA
  • 19.1.2 PRIMARY DATA
• 19.2 MARKET ESTIMATION METHODOLOGY
  • 19.2.1 MARKET SIZE ESTIMATION
  • 19.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 19.2.3 BOTTOM-UP APPROACH
• 19.3 MARKET GROWTH RATE PROJECTIONS
• 19.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS
• 19.7 RISK ANALYSIS

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS